TL;DR
CAG modulates the cell cycle and EMT through the EZH2/PTEN/AKT pathway, effectively overcoming Tmab resistance in HER2-positive BC cells.
The study demonstrates that TFEB regulates the expression of the multidrug efflux transporter ATP-binding cassette subfamily G member 2 (ABCG2), a crucial factor in drug resistance mechanisms, and targets TNKS represents a potentially effective therapeutic approach to address cisplatin resistance and improve treatment...
Capmatinib (CAP) enhances the antitumor activity of PTX in TNBC by targeting c-Met-mediated pathways and shows potential to overcome resistance and improve treatment outcomes in TNBC.
A novel EFO2/USF1/SLC2A1 signaling axis that modulates glycolytic metabolism and CD8⁺T cell cytotoxicity is identified, positioning EFO2 as a promising therapeutic target for TNBC treatment.
T-DXd activates ERK1/2 and ATR, which contributes to resistance, and combining T-DXd with a MEK1/2 inhibitor enhances treatment response, and finding that ERK1/2 plays a key role in activating ATR and causing cell cycle arrest in the G2/M phase is found.
CDC20, upregulated transcriptionally by GATA6 and post-transcriptionally by METTL3, drove CRC progression, angiogenesis, and immune evasion and reversed the inhibitory effects of METTL3 knockdown on CRC cell malignancy and immune escape.
Everolimus inhibits RT-112-RS cell proliferation by suppressing p70S6K activity, and at high concentrations, everolimus can result in activation of the PI3K-Raf1/MEK/ERK pathway possibly by relieving negative feedback inhibition to partially offset its inhibitory effect on cell proliferation.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
